Literature DB >> 6166035

Inhibition of allergen-mediated histamine release from human cells by ketotifen and oxatomide. Comparison with other H1 antihistamines.

M Radermecker.   

Abstract

We have studied the ability of four H1 antihistamines, ketotifen, oxatomide, clemastine and promethazine, and of disodium cromoglycate (DSCG) to inhibit in vitro histamine release mediated by antigen from passively sensitized human lung and from basophilic leukocytes. Anaphylactic histamine release from human leukocytes is inhibited in a comparable fashion by oxatomide, clemastine and promethazine at concentrations just below those inducing histamine release in the absence of antigen. Ketotifen causes a significantly weaker inhibition without inducing histamine release and DSCG is not at all active in this model. On human lung, oxatomide, clemastine and promethazine give a strong and similar inhibition which is linearly related to the dose. Ketotifen markedly differs in this respect, inhibiting according to a bell-shaped dose-response curve and at concentrations closely comparable to that of DSCG. Thus, we confirm that H1 blockers, such as clemastine and promethazine, inhibit anaphylactic histamine release from basophils and human lung but only at high concentrations which may be cytotoxic. Oxatomide behaves very much like these antihistamines. Ketotifen, on the other hand, gives in both models a different pattern of inhibition, closely mimicking that of DSCG. This suggests that the antianaphylactic activity of ketotifen is not related to its H1 blocker properties and that this effect may be relevant to its therapeutic activity.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6166035     DOI: 10.1159/000194358

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  8 in total

Review 1.  Rational use of antihistamines in allergic dermatological conditions.

Authors:  C Advenier; C Queille-Roussel
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

Review 2.  Ketotifen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders.

Authors:  S M Grant; K L Goa; A Fitton; E M Sorkin
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

3.  H1-antihistamines and calmodulin antagonists inhibit the ionophore A23187-induced eicosanoid formation by human leukocytes.

Authors:  T Simmet; W Luck
Journal:  Agents Actions       Date:  1989-03

4.  The mast cell stabilizer ketotifen fumarate lessens contracture severity and myofibroblast hyperplasia: a study of a rabbit model of posttraumatic joint contractures.

Authors:  Michael J Monument; David A Hart; A Dean Befus; Paul T Salo; Mei Zhang; Kevin A Hildebrand
Journal:  J Bone Joint Surg Am       Date:  2010-06       Impact factor: 5.284

5.  The mast cell stabilizer ketotifen reduces joint capsule fibrosis in a rabbit model of post-traumatic joint contractures.

Authors:  Michael J Monument; David A Hart; A Dean Befus; Paul T Salo; Mei Zhang; Kevin A Hildebrand
Journal:  Inflamm Res       Date:  2011-12-16       Impact factor: 4.575

6.  Time-course of the histamine release from human peripheral blood monocytes and the influence of ketotifen and disodium cromoglycate (DSCG).

Authors:  G Zwadlo-Klarwasser; U Braam; C Jungbluth; W Schmutzler
Journal:  Inflamm Res       Date:  1995-04       Impact factor: 4.575

7.  Mast cell expression of the serotonin1A receptor in guinea pig and human intestine.

Authors:  Guo-Du Wang; Xi-Yu Wang; Fei Zou; Meihua Qu; Sumei Liu; Guijun Fei; Yun Xia; Bradley J Needleman; Dean J Mikami; Jackie D Wood
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-03-21       Impact factor: 4.052

Review 8.  Oxatomide. A review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  D M Richards; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-03       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.